Pharmacyclics, Inc. has received a $7 million milestone payment from Les Laboratoires Servier (Servier) for its histone deacetylase (HDAC) inhibitor, PCI-24781 / S 78454. The companies began collaborating in April 2009. Servier has conducted several Phase I/II trials in solid tumors and hematologic malignancies and is now focused on its Phase II programs to establish a registration pathway for PCI-24781 / S 78454. “Servier is delighted to work with Pharmacyclics under this partnership,” said ...